VisiVite reports upcoming release of ProVision macular health formula

NewsGuard 100/100 Score

VisiVite®, a world leader in ocular nutrition, today announced its upcoming January 2015 release of ProVision™, a professional macular health formula designed to be easy for eye doctors to dispense and affordable for their patients to use. Based on the antioxidant supplement used in The National Eye Institute's (NEI) AREDS 2 study, ProVision™ leverages today's best research on nutritional support for macular health to create an accessible, reliable and effective vision health supplement for everyone.

The NEI's AREDS study found that an antioxidant complex supplement appeared to reduce the risk of advanced macular health concerns by 25% over a five year period. The AREDS 2 study followed up with an enhanced supplement, discovering, among other insights, that the macula-supportive botanical nutrients lutein and zeaxanthin were 18% more absorbable and effective than the original AREDS formula (which instead used beta-carotene). These results seemed to suggest the AREDS 2 combination might be even more effective than the original formula.

Despite the promise of the AREDS 2 formula, some eye health professionals have faced challenges in persuading their patients to take it. AREDS 2 supplements can be expensive, with some using luxury ingredients and marketing campaigns that inflate pricing without conferring any benefit. Other AREDS 2 supplements may be inconvenient for patients, often supplying a mere 30-day supply of chalky hard-to-swallow tablets. Of particular concern for eye doctors who distribute vision health supplements to their patients, some AREDS 2 eye supplements may be formulated and manufactured by unknown parties who lack a strong track record.

Formulated by Dr. Paul Krawitz, acclaimed ophthalmologist and university professor, Vitamin Science, Inc. C.E.O., and VisiVite product formulator, ProVision makes it easier for eye health professionals to confidently recommend a quality AREDS 2 formula while improving their patients' compliance for optimal eye health benefits.

"With ProVision, eye doctors get the simplicity of recommending an affordable, doctor-formulated AREDS 2 macular health supplement made by VisiVite, a true leader in ocular nutrition," explains Krawitz. "Patients get an evidence-based means of supporting their vision that's affordable and easy to take: Just two easy-to-swallow softgels daily supply therapeutic antioxidant levels, and a single bottle lasts 90 days so patients only need to buy it four times per year."

ProVision's foundation formula for supporting macular health and vision wellness includes six key antioxidants from the AREDS 2 study calibrated in precise levels:

  • Vitamin C 500 mg
  • Vitamin E 400 IU
  • Zinc 25 mg
  • Copper 1 mg
  • Lutein 10 mg
  • Zeaxanthin 2 mg

"Focusing on eye vitamins exclusively since 2001, VisiVite has ocular nutrition down to a science," continues Krawitz. "With longstanding raw material supplier relationships, formulating expertise and manufacturing efficiency, we're uniquely qualified to make effective eye vitamins that are affordable for everyone. ProVision exemplifies this philosophy, and we're truly proud to announce its forthcoming release in January of 2015."

VisiVite ProVision will be distributed exclusively by eye health professionals. It will first be officially launched at Vision Expo East in New York, March 20-22, 2015, in demi-cases of 12 bottles.

Source:

Vitamin Science, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis